Janux Therapeutics, Inc.
JANX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,878 | $472 | $546 | $814 |
| - Cash | $431 | $19 | $51 | $36 |
| + Debt | $23 | $25 | $25 | $0 |
| Enterprise Value | $2,470 | $478 | $520 | $778 |
| Revenue | $11 | $8 | $9 | $4 |
| % Growth | 31% | -6.1% | 136.8% | – |
| Gross Profit | $9 | $6 | $8 | $4 |
| % Margin | 80.5% | 75.8% | 90.2% | 100% |
| EBITDA | -$97 | -$71 | -$66 | -$33 |
| % Margin | -914.1% | -878.7% | -769.3% | -902.3% |
| Net Income | -$69 | -$58 | -$63 | -$33 |
| % Margin | -651.6% | -721.2% | -732.2% | -898.3% |
| EPS Diluted | -1.28 | -1.32 | -1.52 | -0.79 |
| % Growth | 3% | 13.2% | -92.4% | – |
| Operating Cash Flow | -$44 | -$51 | -$43 | -$17 |
| Capital Expenditures | -$0 | -$2 | -$6 | -$1 |
| Free Cash Flow | -$44 | -$52 | -$49 | -$18 |